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Abstract:  Three lipocyclopeptides, aspartocins A (1), B (2), and C (3), were obtained from the aspartocin 
complex by reversed-phase HPLC separation. Their structures were elucidated by spectroscopic studies coupled 
with the previously published chemical degradation results. All three compounds, 1, 2, and 3, share the same 
cyclic decapeptide core of cyclo(Dab2-Pip3-MeAsp4-Asp5-Gly6-Asp7-Gly8-Dab9-Val10-Pro11-). They differ 
only in the side chain moiety corresponding to Asp1-isotetradecenoic acid, Asp1-anteisotetradecenoic acid, and 
Asp1-isotridecenoic  acid  for  aspartocins  A,  B,  and  C,  respectively.  The  cyclic  substructure  of  aspartocins 
contains two D-amino acid residues, and the geometry of the peptide linkages appears to be all trans including 
the two tertiary amide bonds. The result is consistent with the hypothesis that a normal peptide to be cyclic 
requires D-configured residues or cis amide bond(s) incorporated.  
   
Keywords:  Lipopeptide antibiotics; cyclopeptide requirement; trans and cis amide bonds; L- and D-amino acid 
residues; pipecolic acid conformation; NMR spectroscopy 
 
 
1. Introduction 
 
The lipopeptide antibiotics as a class include a large number of cyclic peptides [1] including 
amphomycin [2] and recently marketed Cubicin® (daptomycin) [3]. Amphomycin, a highly surface-
active lipopeptide mixture, was introduced in the United States in the 1960s  as a calcium salt in 
ointments  for  topical  use  [4],  and  was  later  patented  as  a  feed  additive  [5].  Amphomycin  was 
described as the first member of a series of closely related peptide antibiotics including glumamycin, 
aspartocin, laspartomycin, zaomycin, crystallomycin, and tsushimycin [6]. Although the amphomycin 
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complex was first isolated from a soil actinomycete in 1953 [2], details of its structure were unknown 
until 1972 when Bodanszky proposed a linear lipopeptide structure for amphomycin containing a C-
terminal diketopiperazine moiety [6]. The linear structure was later found to be incorrect by Vertesy et 
al.  in  2000  who  proposed  a  cyclic  structure  for  amphomycin  [7].  Our  degradation  study  of  the 
glycinocin  antibiotics,  structurally  related  to  amphomycin,  showed  that  the  diketopiperazine-
containing fragments were hydrolytic artifacts [8]. This result provides additional evidence that this 
antibiotic  family,  typified  by  amphomycin,  does  contain  a  cyclic  peptide  core.  Very  recently, 
laspartomycin C has been described as the major component of the original laspartomycin complex 
[9]. Laspartomycin C is identical to glycinocin A [9]. 
  The aspartocin complex, an acidic lipopeptide antibiotic mixture, was produced by two soil 
isolates Streptomyces griseus var. spiralis and Streptomyces violaceus [10]. As reported previously, 
eight amino acids, L-aspartic acid, L-proline, L-valine, glycine [10], D-pipecolic acid, β-methyl-L-
aspartic acid, α,β-diaminobutyric acid [11], D-erythro and L-threo α,β-diaminobutyric acids [12], and 
two  fatty  acids,  13-methyl-3-tetradecenoic  acid  and  (+)-12-methyl-3-tetradecenoic  acid  [13],  were 
identified from the acid hydrolysate of the antibiotic complex. However, the complete structure of 
aspartocin  has  never  been  reported,  although  several  articles  suggested  that  it  was  identical  to 
amphomycin in the peptide part of the molecule [6] and its principal constituent was identical to A-
1437 G [7]. Adding to the confusion, the term aspartocin was also used to describe an oxytocin-like 
hormone  in  articles  published  in  1972  [14-15].  Since  we  had  archived  a  sample  of  the  original 
aspartocin  complex,  we  reinvestigated  its  composition  by  HPLC  separation  and  spectroscopic 
structural elucidation for each separated component. The results of our analyses are presented herein 
(Figure 1). 
 
2. Materials and Methods 
 
2.1 General  
 
Electrospray mass spectra and MS-MS data were measured on a Micromass Q-TOF I mass 
spectrometer. High resolution mass spectra were recorded on a 9.4 Tesla FT-ICR mass spectrometer. 
NMR spectra were recorded on a Bruker DRX 500 or DPX 400 spectrometer in deuterated solvents. 
1H-NMR  and 
13C-NMR  chemical  shifts  were  measured  in  parts  per  million  relative  to  partially 
deuterated solvent peaks of DMSO-d6 at δ 2.49 and δ 39.5, and MeOH-d4 at δ 3.30 and δ 49.0 for 
1H-
NMR and 
13C-NMR
 signals, respectively. All 2D experiments were run non-spinning.  
2.2 HPLC Systems 
 
A Hewlett-Packard 1100M LC system with diode array detection and a Finnigan LCQ LC-MS 
system employing a YMC-ODS-A reversed-phase column (5µ, 4.6 x 150 mm) were used for analysis 
of preparative HPLC fractions. Preparative HPLC separations were accomplished on an YMC-Pack 
ODS-A (C18, 250 x 10 mm) column. Fractions from preparative column were generally collected 
using an ISCO Foxy fractional collector and monitored by analytical HPLC or LC-MS. All solvents 
used were obtained from EM Science or J. T. Baker, Inc., and were of the highest commercially 
available purity. 
2.3 Separation 
   
Aspartocin complex (0.11 gram, Batch 3146C-165) was dissolved in a solution of MeOH:H2O 
(4:1, 3 ml) and centrifuged. The supernatant was repeatedly injected into a Hewlett-Packard 1100M 
LC system equipped with a reversed-phase HPLC column (YMC-Pack, ODS-A, 250 x 10 mm). The 
column was washed with a gradient of 45-52% acetonitrile in 0.05% trifluoroacetic acid buffer over 25 
minutes  at  a flow  rate of  4  ml/min.  The  peaks were  detected by UV  absorbance  at 215 nm  and 
collected by a fractional collector. Fractions corresponding aspartocins A to C from each HPLC run Kong et.al., Rec. Nat. Prod. (2010) 4:2 131-140 
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were combined and concentrated to dryness by Speed-Vac and lyophilization to yield white powders 
(1, 15.2 mg; 2, 14.7 mg; 3, 3.5 mg). A typical chromatogram of the aspartocin complex is shown in 
Figure 2. Aspartocin A eluted out at 23.6 minutes, aspartocin B at 22.7 minutes, and aspartocin C at 
17.5 minutes. 
 
3.  Results and Discussion   
The aspartocin antibiotic complex was isolated from the fermentation broth as a calcium salt 
[10]. The complex consisted of three main analogs, aspartocin A (1), aspartocin B (2), and aspartocin 
C  (3).  These  three  analogs  were  separated  using  reversed-phase  HPLC  with  detection  by  UV 
absorbance at 215 nm. Aspartocins A and B are the major components occurring in a nearly 1:1 ratio 
and aspartocin C is a minor component (Figure 2). Based on their respective retention times, the major 
components have similar polarities whereas the minor one is more polar. Semi-preparative HPLC 
separation of the aspartocin complex led to the isolation of these three components, aspartocins A, B, 
and C, in milligram quantities. All compounds were finally obtained as white amorphous powders 
after lyophilization. 
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Figure 1.  Structures of Aspartocins A (1), B (2), and C (3) 
   
Aspartocin A (1) was obtained from the HPLC mobile phase as the free acid, whereas the original 
aspartocin  complex was  a calcium  salt.  Aspartocin A  had  a nondescript UV  absorption  spectrum 
showing only end absorption (Supporting Information). High resolution FT-ICR mass spectrometry 
yielded  a  quasi  molecular  ion  at  m/z  1318.6905  ([M  +  H]
+,  calcd:  1318.6889),  consistent  with  a 
molecular formula of C60H95N13O20.  Consideration of the molecular formula in conjunction with the 
previously published amino acid and fatty acid composition indicated that at least a portion of the 
molecule was cyclic.  
  Visual  inspection  of  the  NMR  data  acquired  on  1  suggested  that  the  molecule  was  a 
lipopeptide. Identification of the fatty acid chain with one double bond present in the molecule was 
straightforward. The proton NMR spectrum of 1 showed two olefinic proton resonances both at δ 5.56 
(H-3  and  H-4)  with  a  complex  splitting  pattern.  The  enhanced  resolution  afforded  by  1D  NMR 
analysis at higher field (600 MHz) was inadequate to define the coupling constants and thereby assign 
olefinic geometry. However, a 
13C coupled HSQC experiment with CW homonuclear 
1H decoupling at 
~3ppm clearly showed the double bond to be in the Z-configuration as H-3 has a coupling constant of Structures of the aspartocin antibiotics 
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11.3 Hz with H-4 (Figure 3). In the HSQC spectrum, H-2 at δ 2.94 was attached to a carbon resonance 
at δ 29.0 (C-2) and H-5 was correlated to a carbon signal at δ 26.9 (C-5), typical chemical shifts for cis 
allylic carbons. A methyl doublet at δ 0.82, integrating for six protons, was evidence that the fatty acid 
chain terminated in an isopropyl group. The length of the fatty chain was revealed by the MS data 
(vide infra). Detailed analyses of the 1D and 2D NMR data confirmed the lipid chain as a 13-methyl-
3-tetradecenoyl moiety, which had previously been reported from the acid hydrolysates of the complex 
[13].  
 
 
 
Figure 2.  The aspartocin complex is composed of three analogs, aspatocin A (1), aspartocin 
B (2), and aspartocin C (3) 
  The  peptidic  nature  of  aspartocin  A  was  apparent  from  the  observation  in  the 
1H  NMR 
spectrum of a series of exchangeable amide proton signals between δ 7.0 and δ 10.0 depending on 
which NMR solvents were used. These amide signals were coupled to the amino acid residue’s α-
protons between δ 3.0 and 5.0. Full assignments of the proton and carbon signals for all residues and 
determination of the sequence of the residues proved to be very challenging. This was due to the poor 
quality of spectra caused by limited solubility and existence of multiple conformers giving rise to 
significant line broadening even with mixtures of acetonitrile and water [7]. Ultimately, given the 
reported composition of amino acids and detailed analyses of the NMR data acquired in deuterated 
methanol,  deuterated  DMSO,  and  mixture  of  water  and  deuterated  acetonitrile,  all  the  NMR 
assignments for aspartocin A were accomplished.  
 
 
Figure 3.  
13C coupled HSQC experiment with CW homonuclear 
1H decoupling  
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  Table 1. 
1H and 
13C NMR assignments for aspartocin A (1) in DMSO-d6 and aspartocin B (2) 
in MeOH-d4 
Aspartocin A (1)       Aspartocin B (2)   
Residue 
   
Position  δH/500 MHz   δC
 a  δH/400 MHz  
 δC 
Asp1  NH  8.23    -   
  α  4.65  49.0  4.79  51.6 
  β  2.50/ 2.60  36.0  2.89/ 2.73  36.3 
Dab2  NH  7.37    -   
  α  4.88  53.0  5.01  55.1 
  β  4.42  50.0  4.47  47.6 
  γ  0.99  18.9  1.14  18.1 
  β-NH  7.95    -   
Pip3  α  4.90  53.3  4.72  56.8 
  β  2.22/ 1.39  27.2  2.06/ 1.79  27.0 
  γ  1.47/ 1.38  20.5  1.63/ 1.51  20.8 
  δ  1.50  24.5  1.77  25.1 
  ε  3.87/ 3.68  42.6  3.88/ 3.51  44.8 
Me-Asp4  NH  8.85    -   
  α  5.05  52.8  4.50  56.5 
  β  2.80  42.3  3.17  40.6 
  γ  0.88  14.1  1.19  14.6 
Asp5  NH  8.77    -   
  α  4.24  51.2  4.59  52.5 
  β  2.51  36.0  3.05/ 2.88  36.3 
Gly6  NH  8.45    -   
  α  3.94/ 3.46  43.0  4.06/ 3.92  44.3 
Asp7  NH  7.55    -   
  α  4.28  50.8  4.50  52.3 
  β  3.00/ 2.20  36.3  3.04 2.75  36.0 
Gly8  NH  8.21    -   
  α  3.98/ 3.44  43.1  3.92/ 3.89  44.3 
Dab9  NH  9.66    -   
  α  4.30  56.0  4.71  55.3 
  β  3.20  47.4  3.82  49.5 
  γ  1.21  17.4  1.33  15.9 
Val10  NH  7.00    -   
  α  3.83  61.2  4.39  58.7 
  β  2.19  29.4  2.16  31.3 
  γ  0.98  18.9  1.05  19.9 
  γ’  0.94  19.7  0.96  18.9 
Pro11  α  4.15  59.6  4.27  61.9 
1  β  2.10/ 1.71  29.4  2.22/ 1.88  31.0 
3  γ  1.89/ 1.80  24.9  2.05/ 1.94  26.1 
  δ  3.77/ 3.56  47.3  3.90/ 3.66  49.2 
FA  1         174.3 
  2  2.94  34.0  3.06  35.6 
  3  5.56  121.2  5.53  122.8 
  4  5.62  133.1  5.56  134.8 
  5  1.99  27.0  2.08  28.4 
  6  1.29  29.0  1.36  30.4 
  7-9  1.23  29.0-29.5  1.30  30.6-31.1 
  10  1.23  29.0-29.5  1.28  28.2 
  11  1.23  26.8  1.09/ 1.30  37.8 
  12  1.13  38.3  1.29  35.8 
  13  1.49  27.3  1.14/ 1.32  30.6 
  14  0.84   22.4  0.87  11.7 
  12-Me      0.85  19.7 
  13-Me  0.84   22.4     
a 
13C chemical shifts were extracted from the 2D spectra. Structures of the aspartocin antibiotics 
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The data set from NMR experiments in DMSO was chosen to report here as the amide proton 
signals from the major conformer showed the important sequence information. Detailed analyses of 
the COSY, TOCSY, HSQC-TOCSY, and HSQC spectra allowed assignment of the proton and carbon 
resonances for each spin system through their 
1H-
1H and 
1H-
13C correlations. As a result, all eleven 
amino acid residues, three Asp, two Gly, two Dab, one Pip, one MeAsp, one Val, and one Pro, were 
characterized.  The  proton and  carbon  chemical  shifts  are  listed  in  Table  1.  The  identity  of these 
individual residues was consistent with the literature information reported previously from the acid 
hydrolysate of the antibiotic complex [10-13].  
  The sequence for aspartocin A was mainly determined by analysis of the NOESY and ROESY 
data. This was achieved by observing the NOESY correlations between the amide protons of adjacent 
residues. In the amide proton region between δ 7.0 and δ 10.0 two coupling systems were observed. 
One involved the most upfield signal at δ 7.00 that exhibited a cross-peak at δ 9.66 and the latter was 
also  correlated  to  a  resonance  at  δ  8.20;  the  δ  8.20  signal  was  further  correlated  to  δ  7.55,  and 
continued from δ 7.55 to δ 8.45, from δ 8.45 to δ 8.75, and finally from δ 8.75 to δ 8.85. These signals 
were  assigned  to  the  amide  protons  of  Val10,  Dab9,  Gly8,  Asp7,  Gly6,  Asp5,  and  MeAsp4, 
respectively, establishing the partial sequence Val-Dab-Gly-Asp-Gly-Asp-MeAsp. The other system 
involved correlations observed from the signal at δ 8.22 to the signal at δ 7.37 and from the signal at δ 
7.37 to the signal at δ 7.95. These signals were assigned to the amide protons of the side chain Asp1 
and Dab2’s α and β amino groups, respectively (Supporting Information).These NOESY correlations 
were  observed  using  a  400-ms  mixing  period  and  were  caused  by  spin  diffusion.  Moreover,  the 
NOESY and ROESY correlations observed between the NH and the α-proton of the preceding residue 
at every amide bond supported the above assignment. The lack of correlations between α-protons of 
neighboring residues further supported the all-trans nature of the amide bonds. The remaining portion 
of the molecule’s linear sequence was established by correlations between the NH (δ 8.85) of MeAs4 
and the α-proton (δ 4.90) of Pip3, and between the β-NH (δ 7.95) of Dab2 and the α-proton (δ 4.15) 
of Pro11, and between the NH (δ 8.23) of Asp1 and the α-protons (δ 2.94) of the fatty chain.   
  Finally,  the  connectivity  between  Val10  and  Pro11  within  the  cyclic  peptide  core  was 
determined by analysis of the MS-MS data. The sequence determination of cyclic peptides is generally 
not practical by MS-MS, because a very complex spectrum is generated due to many combinations of 
two  bond  cleavages  [16].  However,  in  the  case  of  aspartocin  A,  the  tertiary  peptide  linkage  of 
Dab2/Pip3 was favored for protonation, resulting in initial cleavage between the diaminobutyric acid 
and  protonated  pipecolic  acid  residues.  Subsequent  MS-MS  fragmentation  generated  a  series  of 
fragments at m/z 1207, 1078, 963, 535, corresponding to sequential losses of Pip3, MeAsp4, Asp5, and 
Gly6-Asp-Gly-Dab-Val10,  respectively,  supporting  the  Val10  and  Pro11  linkage  for  the  molecule 
(Figure 4). Other key fragment at m/z 981 represented the cyclic peptide core. The length of the fatty 
acid chain was revealed by the fragments at m/z 338 and 310, corresponding to the Asp1-FA side 
chain and loss of a carbonyl group, respectively, as shown. All MS-MS information was consistent 
with the cyclic  peptide  structure of 1  as  shown in Figure  1 [17]. It  should be  noted that for the 
glycinocin peptides that are closely related to aspartocins, the preferred protonation site is the tertiary 
peptide linkage of the proline residue rather than the pipecolic acid one [8]. 
  The information of absolute configurations of the amino acids  comes from the previously 
published data determined from the hydrolysate of the aspartocin complex. Thus, they are L-aspartic 
acid, L-proline, L-valine [10], D-pipecolic acid, β-methyl-L-aspartic acid, D-erythro and L-threo α,β-
diaminobutyric acids [11, 12]. By analogy to the absolute stereochemistry of amphomycin [6] and 
glycinocins [8], which both contain a cyclodecapeptide core and two D-amino acid residues, it is 
assumed that the D-erythro α,β-diaminobutyric acid is for residue-9 (Dab9) and the L-threo one is for 
residue-2 (Dab2) to meet the spatial arrangement requirement. Therefore, the structure of aspartocin A 
with stereochemistry, as depicted in Figure 1, is a cyclodecapeptide with an acyl-Asp side chain. It is 
important to note that the cyclic core contains two D-amino acid residues (Pip3 and Dab9) and two 
tertiary amide bonds (Pip3 and Pro11). Kong et.al., Rec. Nat. Prod. (2010) 4:2 131-140 
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  Interestingly, many cyclopeptides and cyclodepsipeptides contain two D-amino acid residues 
such as mannopeptimycins [18], gramicidin S [1], and daptomycin (Cubicin) [3]. It is well known that 
a peptide consisting of all L-amino acid residues adapts the α-helical backbone conformation and 
therefore  cannot  form  a  cyclic  structure.  It  has  been  long  speculated  that  a  minimum  of  two  D-
configured  amino  acid  residues  is  required  for  a  peptide  to  be  cyclic.  Unless  a  peptide  contains 
residues with no side chain (glycine) or small side chains like alanine and serine, and approaches a 
flat-sheet structure, it is unlikely to form a cyclic structure without the incorporation of D-configured 
residues. Cyclopeptides with a combination of glycine residues  and one D-configured amino acid 
residue fit into this group [19]. However, if there is a cis amide bond present, which usually occurs at 
an N-alkyl peptide site, the peptide backbone of the α-helix (all L-amino acid residues) is disrupted to 
make a turn to form the cyclic structure. Examples include many proline rich cyclic peptides with at 
least one cis amide bond such as pseudoaxinellin [20], hymenamides [21], and cycloleonurinin [22]. 
The role a cis peptide linkage plays is more apparent in the simplest cyclopeptide diketopiperazine that 
contains two cis amide bonds. 
  Tertiary amide bonds in a molecule can exist either in trans or cis conformation in solution 
due to the partial double bond character of the carbon-nitrogen bond and comparable steric effects 
between the two rotamers. The NMR data indicated that the geometry of the two tertiary amide bonds 
in 1 appeared to be all trans. The chemical shifts of Cβ (δ 29.4) and Cγ (δ 24.9) of the proline residue 
supported  the  trans  conformation  of  the  Pro11  amide  bond  [20-22].  The  assignment  of  trans 
conformation for the Pip3’s tertiary amide bond was derived by analogy to the NMR investigation of 
trans and cis rotamers of rapamycin [23-24]. The proton and carbon chemical shifts of the α and ε 
positions of the pipecolic acid residue have unique patterns for the trans and cis isomers. The pattern 
of NMR signals at the α (δH 4.90/ δC 53.3) and ε (δH 3.68, 3.87/ δC 42.6) positions of Pip3 revealed 
that it was the trans rotamer. This result is apparently different from the Pip3’s tertiary amide bond 
conformation of glycinocins that appears to be the cis rotamer based on the characteristic chemical 
shifts at positions α (δH 4.79/ δC 56.2) and ε (δH 2.86, 4.33/ δC 39.9) [8]. The magnitude of the α-
positioned chemical  shifts indicates that  for  the  trans  rotamer,  the  pipecolinyl’s carboxylic  group 
appears to be in axial orientation and its α-proton equatorial as shown in Figure 1. This is consistent 
with the pipecolinyl ring conformation of the major isomer of rapamycin that has been determined to 
be trans both by NMR and X-ray analyses. For the case of glycinocin A, the pipecolinyl amide bond is 
in cis geometry as evidenced by a strong ROESY correlation observed between the α-proton of Pip3 
and α-proton of Dap2. Therefore, it is possible to predict the correct conformation by a comparison of 
characteristic  chemical  shifts  with  the  corresponding  values  for  the  pipecolinyl  residue.  The 
assignment of the carbon chemical shift of αC-Pip3 at δ 53.3 (aspartocin A) for the trans amide bond 
and δ 56.2 (glycinocin A) for the cis one is further supported by the literature data. It is well known 
that  the  carbon  resonance  of  an  amide  N-carbon  with  the  cis  geometry  is  shifted  about  3ppm 
downfield in comparison with the corresponding trans one [25].  
Aspartocin B (2) was isolated as a white powder. Its molecular formula was established by 
high  resolution  FT-ICR  mass  spectrometry  as  C60H95N13O20  (measured  1340.6675,  calculated 
1340.6708 for [M + Na]
+), identical to compound 1. The 
1H NMR spectrum of 2 was nearly identical 
to  that  recorded  for  1  in  MeOH-d4,  indicating  that  the  two  compounds  were  closely  related 
(Supporting Information). In fact, the quality of the NMR data for aspartocins in deuterated methanol 
was  better  than  in  deuterated  DMSO,  however,  this  resulted  in  the  loss  of  the  amide  proton 
information. Detailed analyses of the 
1H-NMR, 
13C-NMR, COSY, HSQC, and HMBC spectra allowed 
us to assign the proton and carbon resonances for aspartocin B, listed in Table 1. Another commonly 
accepted  approach  to  predict  the  amide  bond  geometry  of  a  proline  residue  is  to  compare  the 
difference of the Cβ and Cγ’s chemical shifts [21,22]. The difference (∆β-γ value of 5 ppm) of chemical 
shifts of Cβ (δ 31.0) and Cγ (δ 26.1) of Pro11 and the difference (∆α-ε value of 12 ppm) of Cα (δ 56.8) 
and  Cε  (δ  44.8)  of  Pip3  indicated  that  both  tertiary  amide  bonds  adopted  trans  conformation  in 
methanol as well. The MS-MS fragmentation of 2 showed that it had the same cyclic core at m/z 981 Structures of the aspartocin antibiotics 
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and same size of the side chain at m/z 338 and 310. Therefore, aspartocin B was identified to contain 
the same cyclic core of cyclo-(Dab2-Pip3-MeAsp4-Asp5-Gly6-Asp7-Gly8-Dab9-Val10-Pro11-) with 
Asp1-anteisotetradecenoyl acid side chain as depicted in Figure 1. The absolute stereochemistry for 
the fatty moiety was determined previously as (+)-12-methyl-3-tetradecenoic acid [13]. Aspartocin B 
is identical to A-1437 G [7]. 
  Aspartocin  C  (3)  is  a  white  powder  whose  molecular  formula  was  determined  to  be 
C59H93N13O20  by  high  resolution  FT-ICR  mass  spectrometry  (measured  1304.6734,  calculated 
1304.6733 for [M + H]
+). It only differed from the molecular formula of aspartocin A by the loss of a 
CH2 unit. The MS-MS spectrum of 3 showed the identical fragmentation pattern as that of 1, revealing 
that it differed from 1 only in the fatty chain. The 
1H NMR spectrum of 3 was almost identical to that 
recorded for 1 in MeOH-d4, (Supporting Information). Therefore, aspartocin C was identified as cyclo-
(Dab2-Pip3-MeAsp4-Asp5-Gly6-Asp7-Gly8-Dab9-Val10-Pro11-)  with  Asp1-isotridecenoyl  side 
chain as shown in Figure 1. Aspartocin C (3) is identical to A-1437 B [7].  
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Figure 4. MS/MS fragmentation pattern of aspartocin A (1) 
 
 
4. Conclusion 
The aspartocin complex is composed of three main components, aspartocins A, B, and C. 
Their structures are determined as a cyclic peptide core of cyclo-(Dab2-Pip3-MeAsp4-Asp5-Gly6-
Asp7-Gly8-Dab9-Val10-Pro11-) with an Asp1-FA side chain attached at Dab2’s α-amino group. They 
differ  only  in  the  fatty  acid  part  of  side  chain  as  13-methyl-3-tetradecenoyl,  12-methyl-3-
tetradecenoyl, and 12-methyl-3-tridecenoyl for aspartocins A, B, and C, respectively. Aspartocins are 
structurally related to the revised  structure of amphomycin with the same  cyclic peptide core but 
differing in the fatty chain. Ironically, the revised structure of amphomycin is identical to one of the 
two possible structures originally proposed by Fujino in 1965 for glumamycin [26]. Additionally, the 
  (M+2H)
2+ Kong et.al., Rec. Nat. Prod. (2010) 4:2 131-140 
 
 
139 
term aspartocin used for an oxytocin-type hormone with molecular formula C42H64N12O12S2 should be 
avoided [14-15].
  
   The cyclic substructure of aspartocins contains two D-amino acid residues, supporting the 
hypothesis that a minimum of two D-configured residues or cis amide bond(s) is required for a peptide 
to be cyclic. The geometry of the two tertiary amide bonds (Pip3 and Pro11) in the molecule appears 
to be all trans. It has been well accepted that the characteristic chemical shifts of Cβ and Cγ of a 
proline residue are consistent with the geometry of the prolinyl amide bond. Likewise, it is possible to 
predict the amide bond geometry as well as the pipecolinyl ring  conformation only based on the 
unique chemical shifts of Cα and Cε of a pipecolic acid residue. 
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